Blinatumomab (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Blinatumomab" in English language version.
refsWebsite
Global rank
English rank
3,984th place
2,622nd place
3,257th place
3,398th place
1st place
1st place
low place
7,595th place
99th place
77th place
low place
low place
ama-assn.org
- "Blinatumomab" (PDF). American Medical Association. 2008. N08/16.
amgen.com
- "Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia" (Press release). Amgen. 1 July 2014.
- "Amgen's BiTE Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia" (Press release). Amgen. 9 October 2014.
bbc.com
- "Exciting new cancer drug kinder than chemotherapy". BBC News. 17 January 2024. Retrieved 17 January 2024.
biospace.com
bloomberg.com
- Lopatto E. "Amgen to Buy Micromet for $1.16 Billion for Leukemia Drug". Bloomberg.
canada.ca
health-products.canada.ca
- "Blincyto Product information". Health Canada. 17 March 2016. Retrieved 12 March 2025.
canada.ca
- "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
doi.org
- Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. (March 2007). "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis". Molecular Immunology. 44 (8): 1935–43. doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. (January 2019). "FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease". Clinical Cancer Research. 25 (2): 473–477. doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
drugs.com
- "Blinatumomab (Blincyto) Use During Pregnancy". Drugs.com. 29 May 2018. Retrieved 14 March 2020.
europa.eu
ema.europa.eu
- "Blincyto EPAR". European Medicines Agency (EMA). 24 July 2009. Retrieved 12 March 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
fda.gov
fda.gov
- "FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell" (Press release). U.S. Food and Drug Administration (FDA). 12 July 2017. Retrieved 26 October 2018.
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF) (Report). U.S. Food and Drug Administration (FDA). Blinatumomab (AMG 103). Archived from the original (PDF) on 9 May 2017. Retrieved 16 December 2019.
accessdata.fda.gov
- "Drug Approval Package: Blincyto (blinatumomab) Injection NDA #125557". U.S. Food and Drug Administration (FDA). 12 January 2015. Retrieved 14 March 2020.
fiercepharmamarketing.com
- Staton T (18 December 2014). "Amgen slaps record-breaking $178K price on rare leukemia drug Blincyto". FiercePharmaMarketing.
nih.gov
pubmed.ncbi.nlm.nih.gov
- Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, et al. (March 2007). "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis". Molecular Immunology. 44 (8): 1935–43. doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. (January 2019). "FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease". Clinical Cancer Research. 25 (2): 473–477. doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
dailymed.nlm.nih.gov
- "Blincyto- blinatumomab kit". DailyMed. 19 April 2019. Retrieved 14 March 2020.
tga.gov.au
- "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- "Blincyto (Amgen Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 19 February 2025. Retrieved 7 March 2025.
- "AusPAR: Blinatumomab". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 7 March 2025.
web.archive.org
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF) (Report). U.S. Food and Drug Administration (FDA). Blinatumomab (AMG 103). Archived from the original (PDF) on 9 May 2017. Retrieved 16 December 2019.
wsj.com
- Loftus P (18 June 2015). "How Much Should Cancer Drugs Cost? Memorial Sloan Kettering doctors create pricing calculator that weighs factors such as side effects, extra years of life". The Wall Street Journal. Retrieved 22 June 2015.